Cerebrospinal fluid concentration of Galectin-9 is increased in secondary progressive multiple sclerosis

Journal of Neuroimmunology

Volumn 292, Issue , 2016, Pages 40-44

  Burman, Joachim ^a,b   Svenningsson, Anders ^c,d  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Biomarker; CSF; Galectin 9; Multiple sclerosis

Indexed keywords

ALBUMIN; BIOLOGICAL MARKER; ECALECTIN; GLATIRAMER; IMMUNOGLOBULIN; INTERFERON; MITOXANTRONE; NATALIZUMAB; GALECTIN; LGALS9 PROTEIN, HUMAN;

ADULT; AGE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CEREBROSPINAL FLUID LEVEL; SEX DIFFERENCE; ANALYSIS OF VARIANCE; CEREBROSPINAL FLUID; COHORT ANALYSIS; DISABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; MIDDLE AGED;

ADULT; ANALYSIS OF VARIANCE; COHORT STUDIES; DISABILITY EVALUATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GALECTINS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

EID: 84960889474     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2016.01.008     Document Type: Article

References (31)

1. Anderson A.C., Anderson D.E., Bregoli L., Hastings W.D., Kassam N., Lei C., Chandwaskar R., Karman J., Su E.W., Hirashima M.,., Bruce J.N.,., Kane L.P., Kuchroo V.K., Hafler D.A. Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells. Science 2007, 318:1141-1143.
2. Barondes S.H., Castronovo V., Cooper D.N., Cummings R.D., Drickamer K., Feizi T., Gitt M.A., Hirabayashi J., Hughes C., Kasai K., et al. Galectins: a family of animal beta-galactoside-binding lectins. Cell 1994, 76:597-598.
3. Confavreux C. Natural history of multiple sclerosis: a unifying concept. Brain 2006, 129:606-616.
4. Confavreux C., Vukusic S., Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 2003, 126:770-782.
5. Filippi M., Rossi P., Campi A., Colombo B., Pereira C., Comi G. Serial contrast-enhanced MR in patients with multiple sclerosis and varying levels of disability. Am. J. Neuroradiol. 1997, 18:1549-1556.
6. Frischer J.M., Bramow S., Dal-Bianco A., Lucchinetti C.F., Rauschka H., Schmidbauer M., Laursen H., Sorensen P.S., Lassmann H. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 2009, 132:1175-1189.
7. 11C](R)-PK11195-PET pilot study. Neurobiol. Dis. 2014, 65:203-210.
8. Komori M., Blake A., Greenwood M., Lin Y.C., Kosa P., Ghazali D., Winokur P., Natrajan M., Wuest S.C., Romm E., Panackal A.A., Williamson P.R., Wu T., Bielekova B. CSF markers reveal intrathecal inflammation in progressive multiple sclerosis. Ann. Neurol 2015.
9. Koziol J., Wagner S., Adams H. Assessing information in T2-weighted MRI scans from secondary progressive MS patients. Neurology 1998, 51:228-233.
10. Liu J., Marino M.W., Wong G., Grail D., Dunn A., Bettadapura J., Slavin A.J., Old L., Bernard C.C. TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination. Nat. Med. 1998, 4:78-83.
11. Lublin F., Reingold S. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996, 46:907-911.
12. Malmestrom C., Axelsson M., Lycke J., Zetterberg H., Blennow K., Olsson B. CSF levels of YKL-40 are increased in MS and replaces with immunosuppressive treatment. J. Neuroimmunol. 2014, 269:87-89.
13. Mayo L., Quintana F.J., Weiner H.L. The innate immune system in demyelinating disease. Immunol. Rev. 2012, 1:170-187.
14. Meinl E., Krumbholz M., Derfuss T., Junker A., Hohlfeld R. Compartmentalization of inflammation in the CNS: a major mechanism driving progressive multiple sclerosis. J. Neurol. Sci. 2008, 274:42-44.
15. Oomizu S., Arikawa T., Niki T., Kadowaki T., Ueno M., Nishi N., Yamauchi A., Hattori T., Masaki T., Hirashima M. Cell surface galectin-9 expressing Th cells regulate Th17 and Foxp3+ Treg development by galectin-9 secretion. PLoS One 2012, 7.
16. Polman C.H., Reingold S.C., Banwell B., Clanet M., Cohen J.A., Filippi M., Fujihara K., Havrdova E., Hutchinson M., Kappos L., Lublin F.D., Montalban X., O'connor P., Sandberg-Wollheim M., Thompson A.J., Waubant E., Weinshenker B., Wolinsky J.S. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann. Neurol. 2011, 69:292-302.
17. Prineas J.W., Kwon E.E., Cho E.S., Sharer L.R., Barnett M.H., Oleszak E.L., Hoffman B., Morgan B.P. Immunopathology of secondary-progressive multiple sclerosis. Ann. Neurol. 2001, 50:646-657.
18. 11C-PK11195. J. Nucl. Med 2014.
19. Scalfari A., Neuhaus A., Daumer M., Muraro P.A., Ebers G.C. Onset of secondary progressive phase and long-term evolution of multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 2014, 85:67-75.
20. Seki M., Oomizu S., Sakata K.M., Sakata A., Arikawa T., Watanabe K., Ito K., Takeshita K., Niki T., Saita N., Nishi N., Yamauchi A., Katoh S., Matsukawa A., Kuchroo V., Hirashima M. Galectin-9 suppresses the generation of Th17, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritis. Clin. Immunol. 2008, 127:78-88.
21. Selmaj K.W., Raine C.S. Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann. Neurol. 1988, 23:339-346.
22. Solomon A.J., Spain R.I., Kruer M.C., Bourdette D. Inflammatory neurological disease in patients treated with tumor necrosis factor alpha inhibitors. Mult. Scler. 2011, 17:1472-1487.
23. Sospedra M., Martin R. Immunology of multiple sclerosis. Annu. Rev. Immunol. 2005, 23:683-747.
24. Stancic M., Van Horssen J., Thijssen V.L., Gabius H.J., Van Der Valk P., Hoekstra D., Baron W. Increased expression of distinct galectins in multiple sclerosis lesions. Neuropathol. Appl. Neurobiol. 2011, 37:654-671.
25. Steelman A.J., Li J. Astrocyte galectin-9 potentiates microglial TNF secretion. J. Neuroinflammation 2014, 11:144.
26. Steelman A.J., Smith R., Welsh C.J., Li J. Galectin-9 protein is up-regulated in astrocytes by tumor necrosis factor and promotes encephalitogenic T-cell apoptosis. J. Biol. Chem. 2013, 288:23776-23787.
27. Teunissen C.E., Petzold A., Bennett J.L., Berven F.S., Brundin L., Comabella M., Franciotta D., Frederiksen J.L., Fleming J.O., Furlan R., Hintzen R.Q., Hughes S.G., Johnson M.H., Krasulova E., Kuhle J., Magnone M.C., Rajda C., Rejdak K., Schmidt H.K., Van Pesch V., Waubant E., Wolf C., Giovannoni G., Hemmer B., Tumani H., Deisenhammer F. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology 2009, 73:1914-1922.
28. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS MRI Analysis Group TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 1999, 53:457-465.
29. Wada J., Kanwar Y.S. Identification and characterization of galectin-9, a novel beta-galactoside-binding mammalian lectin. J. Biol. Chem. 1997, 272:6078-6086.
30. Zhu C., Anderson A.C., Schubart A., Xiong H., Imitola J., Khoury S.J., Zheng X.X., Strom T.B., Kuchroo V.K. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat. Immunol. 2005, 6:1245-1252.
31. Zhu C., Anderson A.C., Kuchroo V.K. TIM-3 and its regulatory role in immune responses. Curr. Top. Microbiol. Immunol. 2011, 350:1-15.